Peter Allen joined the board of Oxford Nanopore in 2011, bringing broad, senior experience in the life sciences industries. He currently serves as Non-Executive Chairman on the Boards of ProStrakan Group plc, Chroma Therapeutics Ltd and Proximagen Neuroscience plc.
Previously, Peter was Chief Financial Officer of the electronics company Abacus Group plc from April 2005 until the company was sold to Avnet Inc in January 2009. Prior to this he was Chief Financial Officer of Celltech Group plc between 1992 and 2004. In addition to managing Celltech's flotation process in 1993, Peter played a key role in several strategic acquisitions, including Chiroscience Group plc, Medeva plc and Oxford Glycosciences plc. In 2003 Peter was also appointed Deputy Chief Executive Officer of Celltech until the company was sold to UCB in 2004.